MarketMoodz
FDA approves J&J's Icotyde as oral rival to Tremfya/Skyrizi in psoriasis
Johnson & Johnson won FDA approval for Icotyde, an oral daily pill for moderate-to-severe plaque psoriasis. The move positions J&J to challenge top injectable IL-23 therapies Tremfya and Skyrizi, pending payer access and real-world results.
Key Takeaways
- Icotyde is an oral daily pill approved for moderate-to-severe plaque psoriasis.
- It targets the IL-23 receptor, aligning with Tremfya and Skyrizi's mechanism.
- J&J positions Icotyde as the first oral option to rival top injections (per company materials).
- Dosing is once daily; pricing is not disclosed, while competing injections run about $100,000/year.
- Peak annual sales potential exceeds $5 billion after expansion to other autoimmune diseases.
People Involved
- No specific individuals mentioned
Entities Involved
- Johnson & Johnson (JNJ) Pharmaceutical company developing Icotyde
- Protagonist Therapeutics Development partner in Icotyde program
- AbbVie Developer of Skyrizi (risankizumab)
- Janssen Developer of Tremfya (guselkumab)
MarketMoodz Analysis
The FDA approval marks a potential inflection point in psoriasis treatment dynamics. An oral IL-23 pathway option could alter payer discussions, adherence, and the overall cost curve for systemic therapies if Icotyde demonstrates competitive efficacy and safety.
From a historical lens, oral therapies have struggled to match biologics on durability and safety data, making Icotyde’s performance and real-world uptake critical for investor expectations. If Icotyde makes inroads, it could pressure pricing and widen access, particularly for patients with needle aversion or those seeking at-home options.
Key next watch items include: late-stage efficacy and safety results in broader autoimmune indications, payer coverage and formulary decisions, and the potential for expansion into psoriatic arthritis, ulcerative colitis, and Crohn’s disease, which could unlock multi-billion-dollar peak sales.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial